Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7772440 | 0.90 | MTNR1A (0.47) | ADRA2AMTNR1AMTNR1BCYP1A2MAPT | |
| SCHEMBL7917604 | 0.82 | ADRA2A (0.47) | ADRA2AMTNR1AMTNR1BCYP1A2MAPT | |
| SCHEMBL5835478 | 0.81 | ADRA2A (0.46) | ADRA2AMTNR1AMTNR1BCYP1A2MAPT | |
| SCHEMBL11165552 | 0.77 | ADRA2A (0.48) | ADRA2AMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL5835137 | 0.77 | MTNR1A (0.44) | ADRA2AMTNR1AMTNR1BCYP1A2MAPT | |
| SCHEMBL5835247 | 0.76 | GHSR (0.64) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL1080060 | 0.74 | BRD4 (0.52) | ADRA2AMTNR1AMTNR1BCYP1A2MAPT | |
| Hydrochloric Acid SCHEMBL10914162 | 0.74 | MTNR1A (0.45) | ADRA2AMTNR1AMTNR1BCYP1A2MAPT | |
| SCHEMBL8845587 | 0.73 | MTNR1A (0.45) | ADRA2AMTNR1AMTNR1BCYP1A2MAPT | |
| SCHEMBL5835267 | 0.72 | ADRA2A (0.43) | ADRA2AMTNR1AMTNR1BCYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115767-B2 | Tetraline derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | ABBVIE INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | GPR119, GHSR, GIPR | ADRA2A 553/4885MTNR1A 84/4885MTNR1B 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.